Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck’s Serdolect and AstraZeneca’s Seroquel XR To Face Advisory Panel Review

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA’s Psychopharmacologic Drug Advisory Committee will evaluate the applications for the two antipsychotics in a two day meeting in April.

You may also be interested in...



Metoclopramide Gets Boxed Warning, REMS, For Movement Disorder Risk

FDA issued a class-wide requirement Feb. 26 for metoclopramide-containing products to gain a boxed warning and Risk Evaluation and Mitigation Strategy to address the gastrointestinal drug's associated risk of tardive dyskinesia

AstraZeneca Internal Seroquel Documents Cite Cherry-Picking, Burying Data

AstraZeneca agreed to unseal internal communications in Seroquel product liability litigation discussing risks associated with the drug.

AstraZeneca Submits Seroquel XR In Two Additional Indications

Company is seeking approval of separate sNDAs for treatment of bipolar mania and bipolar depression.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel